Research and Markets: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors Competitor Analysis
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/v5h39c/competitor) has announced the addition of the "Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors" report to their offering.
“Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors”
The present Competitive Intelligence Report about alpha1-proteinase inhibitors (alpha1-PI), alpha1-antitrypsin (AAT) and elastase inhibitors provides a competitor evaluation in the field of human plasma-derived, recombinant, transgenic, synthetic and gene therapeutic approaches for treatment of lung emphysema caused by congenital deficiency and of other diseaes by synthetic elastase inhibitors or RNA approaches as of July 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Neutrophil elastase (NE) is a serine protease, expressed mainly by neutrophils, that is capable of degrading a variety of structural proteins of the extracellular matrix. Infiltration of activated neutrophils and excessive NE activity have been implicated in several lung diseases, including acute lung injury, cystic fibrosis, pulmonary fibrosis, COPD and bronchiectasis.
Endogenous human neutrophil elastase is predominantly neutralized by alpha-1 antitrypsin (AAT), also called alpha1-proteinase inhibitor (alpha1-PI). Congenital deficiency of AAT leads to emphysema which can be treated by substitution with therapeutic AAT. At present, alpha-1 antitrypsin products are human plasma-derived purified products. Recombinant AAT products are under development as well as gene therapy approaches to replace AAT. Downregulation of AAT is presently being evaluated as a therapeutic strategy to treat liver disease associated with Alpha-1 antitrypsin deficiency (AATD). AAT is currently also being evaluated as a treatment option for type 1 diabetes and graft-versus-host disease.
Neutrophil elastase also has attracted much interest as a target for inhibition to treat chronic obstructive pulmonary disease (COPD), asthma or bronchiectasis. Synthetic and recombinant elastase inhibitors have been identified and are in clinical and preclinical development.
The report includes a compilation of current active products and projects in research and development of human neutrophil elastase targeting small molecules, purified and recombinant proteins, peptides, RNA and DNA. In addition, the report lists company-specific R&D pipelines of alpha1-PI, antitrypsin and elastase inhibitors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
1. Substitution with alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
2. Gene Therapy with alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
3. Downregulation of alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
4. Elastase Inhibitors
5. Corporate alpha1-PI, Antitrypsin & Elastase Inhibitor R&D Pipelines
For more information visit http://www.researchandmarkets.com/research/v5h39c/competitor